Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Audentes Therapeutics Inc.

www.audentestx.com

Latest From Audentes Therapeutics Inc.

Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem

The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?

Japan Gene Therapy

Astellas To Pay $3bn For Gene Therapy Company Audentes

Japanese company joins the ranks of big pharma buying up gene therapy pioneers

Asia Pacific Gene Therapy

Audentes' Gene Therapy Allows Ventilator Independence For Rare Disease

Audentes Therapeutics is aiming for regulatory submissions next year for its lead product, a skeletal muscle-targeted gene therapy, which continues to show promise in X-linked myotubular myopathy.

 

 

Rare Diseases Gene Therapy

Deal Watch: Vertex Expands Gene-Editing Efforts With A Pair Of Deals

CF-focused Vertex will buy Exonics and expand a collaboration with CRISPR Therapeutics, with plans to develop therapies for DMD and myotonic dystrophy type 1. Merck acquires TGFβ-focused Tilos, while Achaogen offloads most of its assets at auction.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cardiovascular
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Audentes Therapeutics Inc.
  • Senior Management
  • Matthew R Patterson, Chmn. & CEO
    Thomas Soloway, SVP, CFO
    Edward R Conner, MD, SVP, CMO
    Natalie Holles, Pres. & COO
    Eric B Mosbrooker, SVP, Chief Commercial Officer
  • Contact Info
  • Audentes Therapeutics Inc.
    Phone: (415) 818-1001
    600 California St., 17th Fl.
    San Francisco, CA 94018
    USA
UsernamePublicRestriction

Register